Coordination of 3-aminoquinoxaline-2-carbonitrile 1,4-dioxides to antimony(III) as a strategy for anti-Trypanosoma cruzi activity improvement

Medicinal Chemistry Research

Volumn 21, Issue 12, 2012, Pages 4120-4128

  Varela, Javier ^a   Lessa, Josane Alves ^b   Lavaggi, María Laura ^a   Beraldo, Heloisa ^b   Cerecetto, Hugo ^a   González, Mercedes ^a  

^a UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

3 Aminoquinoxaline 2 carbonitrile 1,4 dioxide; Antimony complexes; Chagas disease; Trypanosoma cruzi

Indexed keywords

ANTIMONY DERIVATIVE; ANTITRYPANOSOMAL AGENT; COORDINATION COMPOUND; CYANIDE; LIGAND; OXIDE; QUINOXALINE;

ANTIPROTOZOAL ACTIVITY; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG SCREENING; EPIMASTIGOTE; IN VITRO STUDY; INFRARED SPECTROSCOPY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTUM YIELD; TRYPANOSOMA CRUZI;

EID: 84455203882     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9955-z     Document Type: Article

References (21)

1. Aguirre G, Cerecetto H, Di Maio R, González M, Alfaro ME, Jaso A, Zarranz B, Ortega MA, Aldana I, Monge-Vega A (2004) Quinoxaline N,N0-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi. Structure-activity relationships. Bioorg Med Chem Lett. 14: 3835-3839
2. Ancizu S, Moreno E, Torres E, Burguete A, Pérez-Silanes S, Benítez D, Villar R, Solano B, Marín A, Aldana I, Cerecetto H, González M, Monge A (2009) Heterocyclic-2-carboxylic acid (3-cyano-1,4-di-N-oxidequinoxalin-2-yl)amide derivatives as hits for the development of neglected disease drugs. Molecules 14: 2256-2272
3. Benitez D, Cabrera M, Hernández P, Boiani L, Lavaggi ML, Di Maio R, Yaluff G, Serna E, Torres S, Ferreira ME, Vera de Bilbao N, Torres E, Pérez-Silanes S, Solano B, Moreno E, Aldana I, López de Ceráin A, Cerecetto H, González M, Monge A (2011) 3-Trifluoromethylquinoxaline N,N0-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies. J Med Chem 54: 3624-3636
4. Benítez D, Lavaggi ML, Gambino D, Torre MH, Cerecetto H, González M (2011) Effect of complexation of 3-aminoquinoxaline-2-carbonitrile 1,4-dioxides with palladium and copper on their anti-T. cruzi activity. Med Chem Res. doi: 10.1007/s00044-011-9660-y
5. Castro JA, de Meca MM, Bartel LC (2006) Toxic side effects of drugs used to treat Chagas’ disease (American trypanosomiasis). Hum Exp Toxicol 25: 471-479
6. Cavalli A, Bolognesi ML (2009) Neglected tropical diseases: multitarget-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania. J Med Chem 52: 7339-7359
7. Cerecetto H, González M (2010) Synthetic medicinal chemistry in Chagas’ disease: compounds at the final stage of '‘Hit-to-Lead’' phase. Pharmaceuticals 3: 810-838
8. Geary WJ (1971) The use of conductivity measurements in organic solvents for the characterisation of coordination compounds. Coord Chem Rev 7: 81-122
9. González M, Cerecetto H (2007) Benzofuroxan and furoxan. Chemistry and Biology. In: M. T. H. Khan (Org.). Topics in heterocyclic chemistry. Bioactive Heterocycles V. Berlin, Springer vol. 10, p. 265-308
10. Kadam RU, Chavan A, Roy N (2007) Pharmacophoric features of Pseudomonas aeruginosa deacetylase LpxC inhibitors: an electronic and structural analysis. Bioorg Med Chem Lett 17: 861-868
11. Lessa JA, Reis DC, Mendes IC, Speziali NL, Rocha LF, Pereira VRA, Melo CML, Beraldo H (2011) Antimony(III) complexes with pyridine-derived thiosemicarbazones: structural studies and investigation on the antitrypanosomal activity. Polyhedron 30: 372-380
12. Menna-Barreto RFS, Salomão K, Dantas AP, Santa-Rita RM, Soares MJ, Barbosa HS, de Castro SL (2009) Different cell death pathways induced by drugs in Trypanosoma cruzi: an ultrastructural study. Micron 40: 157-168
13. Merlino A, González M, Cerecetto H (2010) Targets for anti-T. cruzi drugs in the post-genomic era. Curr Enzym Inhib 6: 195-210
14. Pérez-Rebolledo A, Teixeira LR, Batista AA, Mangrich AS, Aguirre G, Cerecetto H, González M, Hernández P, Ferreira AM, Speziali NL, Beraldo H (2008) 4-Nitroacetophenone-derived thiosemicarbazones and their copper(II) complexes with significant in vitro anti-trypanosomal activity. Eur J Med Chem 43: 939-948
15. Reis DC, Pinto MCX, Souza-Fagundes EM, Rocha LF, Pereira VRA, Melo CML, Beraldo H (2011) Investigation on the pharmacological profile of antimony(III) complexes with hydroxyquinoline derivatives: anti-trypanosomal activity and cytotoxicity against human leukemia cell lines. Biometals 24: 595-601
16. Rodrigues C, Batista AA, Ellena J, Castellano EE, Benítez D, Cerecetto H, González M, Teixeira LR, Beraldo H (2010) Coordination of nitro-thiosemicarbazones to ruthenium(II) as a strategy for anti-trypanosomal activity improvement. Eur J Med Chem 45: 2847-2853
17. Spartan '04 and Spartan '08; Wavefunction, Inc. 18401 Von Karman Avenue, Suite 370. Irvine, California 92612 USA. http://www.wavefun.com
18. Urquiola C, Vieites M, Aguirre G, Marín A, Solano B, Arrambide G, Noblía P, Lavaggi ML, Torre MH, González M, Monge A, Gambino D, Cerecetto H (2006) Improving anti-trypanosomal activity of 3-aminoquinoxaline-2-carbonitrile N1, N4-dioxide derivatives by complexation with vanadium. Bioorg Med Chem 15: 5503-5509
19. Vicente E, Duchowicz PR, Benítez D, Castro EA, Cerecetto H, González M, Monge A (2010) Anti-. cruzi activities and QSAR studies of 3-arylquinoxaline-2-carbonitrile di-N-oxides. Bioorg Med Chem Lett 20: 4831-4835
20. Zamalloa E, Aldana I, Bachiller CM, Monge A (1997a) Physicochemical properties and stability of the new hypoxia-selective agent 7-chloro-3-[[N,N-dimethylamino propyl]amino]-2-quinoxalinecarbonitrile 1,4-di-N-oxide hydrochloride. Arzneimittelforsch 47: 873-878
21. Zamalloa E, Dios-Viéitez C, González-Peña E, Monge A (1997b) Determination of a new hypoxia selective agent from 2-quinoxalinecarbonitrile 1,4-di-N-oxides in plasma by high performance liquid chromatography. Arzneimittelforsch 47: 1044-1046